AU2470595A - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis

Info

Publication number
AU2470595A
AU2470595A AU24705/95A AU2470595A AU2470595A AU 2470595 A AU2470595 A AU 2470595A AU 24705/95 A AU24705/95 A AU 24705/95A AU 2470595 A AU2470595 A AU 2470595A AU 2470595 A AU2470595 A AU 2470595A
Authority
AU
Australia
Prior art keywords
peptide
mbp
amino acid
acid residues
human mbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24705/95A
Other languages
English (en)
Inventor
Di-Hwei Hsu
Jia Dong Shi
Dawn Smilek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of AU2470595A publication Critical patent/AU2470595A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU24705/95A 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis Abandoned AU2470595A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US241246 1994-05-10
US32822494A 1994-10-25 1994-10-25
US328224 1994-10-25
PCT/US1995/005605 WO1995030435A2 (fr) 1994-05-10 1995-05-04 Compositions et traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
AU2470595A true AU2470595A (en) 1995-11-29

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24705/95A Abandoned AU2470595A (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis

Country Status (11)

Country Link
EP (1) EP0758902A1 (fr)
JP (1) JPH10500109A (fr)
AU (1) AU2470595A (fr)
CA (1) CA2189990A1 (fr)
CZ (1) CZ329596A3 (fr)
HU (1) HUT76099A (fr)
IL (1) IL113661A0 (fr)
PL (1) PL317197A1 (fr)
SI (1) SI9520059A (fr)
SK (1) SK145896A3 (fr)
WO (1) WO1995030435A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012737A2 (fr) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions et traitement pour la sclerose en plaques
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2250361A1 (fr) * 1996-03-28 1997-10-02 Barbara Wallner Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations
EP0939826A2 (fr) * 1996-08-15 1999-09-08 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021222A1 (fr) * 1992-04-09 1993-10-28 Autoimmune, Inc. Repression de la proliferation des lymphocytes t grâce a l'utilisation de fragments peptidiques provenant de la proteine de base de la myeline
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制

Also Published As

Publication number Publication date
IL113661A0 (en) 1995-08-31
HU9603116D0 (en) 1997-01-28
JPH10500109A (ja) 1998-01-06
SI9520059A (en) 1997-08-31
PL317197A1 (en) 1997-03-17
WO1995030435A2 (fr) 1995-11-16
HUT76099A (en) 1997-06-30
WO1995030435A3 (fr) 1995-12-07
SK145896A3 (en) 1997-05-07
CA2189990A1 (fr) 1995-11-16
CZ329596A3 (en) 1997-05-14
EP0758902A1 (fr) 1997-02-26

Similar Documents

Publication Publication Date Title
EP0553291B1 (fr) Traitement de maladies auto-immunes par administration orale d'auto-antigenes
EP0359783B2 (fr) Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes
US5733547A (en) Treatment of autoimmune arthritis by oral administration of type I or type III collagen
US5869054A (en) Treatment of multiple sclerosis by oral administration of autoantigens
AU2470595A (en) Compositions and treatment for multiple sclerosis
Samson et al. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes.
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
CA2203629A1 (fr) Compositions et traitement pour la sclerose en plaques
JP2004026797A (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
CA2133749A1 (fr) Suppression de la proliferation de lymphocytes t a l'aide de fragments peptidiques de la proteine de base de la myeline
US6180103B1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
Jung et al. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN.
AU684713B2 (en) Peptide T and related peptides in the treatment of inflammatory bowel disease
US20230172894A1 (en) Combination treatment for fumarate-related diseases
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения